



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/810,506	03/19/2001	Teruaki Taji	204936US0	8250

22850 7590 10/18/2002

OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC
FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202

EXAMINER

COLLINS, CYNTHIA E

ART UNIT	PAPER NUMBER
----------	--------------

1638

DATE MAILED: 10/18/2002

18

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/810,506

Applicant(s)

TAJI ET AL.

Examiner

Cynthia Collins

Art Unit

1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 August 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) 2 and 8 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,3-7 and 9 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 14 August 2001 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☒ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

Art Unit: 1638

DETAILED ACTION***Election/Restrictions***

Applicant's election with traverse of Group II, claims 1, 3-7 and 9, in Paper No. 17 is acknowledged. The traversal is on the ground(s) that Groups I and II describe gene sequences that encode different isoforms of the same proteins, despite possessing divergent sequences, and as such these genes would necessarily be searched together and should not be separated, on the ground(s) that no adequate reasons and/or examples have been provided to support a conclusion of patentable distinctness between the Groups, and on the ground(s) that a search of all the claims would not constitute a serious burden on the Office. This is not found persuasive because, absent Applicant's assertion that the sequences are not patentably distinct, each divergent amino acid sequence is presumed to be patentably distinct, and a separate search is required for each divergent sequence. Furthermore, database and resource allocations at the PTO are such that a search of more than one distinct sequence in the instant application would present a burden on PTO resources. Accordingly, claims 2 and 8 are withdrawn from consideration as being directed to a nonelected invention.

The requirement is still deemed proper and is therefore made FINAL.

Drawings

The drawings are objected to because Line 29 is designated as AtGolS2 suppressed expression Figures 8 and 9, but elsewhere in the specification Line 29 is referred to as AtGolS2

Art Unit: 1638

excessive expression (see for example pages 28-29 and Figures 5-7). A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.

Claim Objections

Claim 1 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 1 is dependent on claim 6, which is not a previous claim.

Claim 1 is objected to because the word galactinol is misspelled. Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1 and 4-6 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.

Art Unit: 1638

The claims are drawn to a method of increasing stress resistance to a plant which comprises increasing galactinol content in the plant body by introducing a galactinol synthetase gene into the plant body.

The specification describes a single method of increasing drought stress resistance to a plant by introducing into and expressing in an *Arabidopsis* plant an isolated nucleic acid obtained from *Arabidopsis* encoding the galactinol synthetase designated AtGolS2 (pages 26-29 and Figures 4-8). This does not constitute a substantial portion of the genus that comprises a galactinol synthetase gene. The claimed genus encompasses a multitude of different nucleotide sequences and proteins, including those yet to be discovered. The disclosure of a single nucleotide sequence that encodes an *Arabidopsis* galactinol synthetase polypeptide that confers drought stress tolerance when expressed in *Arabidopsis* does not provide an adequate description of the claimed genus, and in view of the level of knowledge and skill in the art, one skilled in the art would not recognize from the disclosure that the applicant was in possession of the claimed genus (see Written Description Guidelines, Federal Register, Vol. 66, No. 4, January 5, 2001, pages 1099-1111).

Claims 1, 3-7 and 9 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method for increasing drought stress resistance in a plant by introducing into a plant and expressing an isolated nucleic acid encoding the galactinol synthetase designated AtGolS2, does not reasonably provide enablement for methods for increasing stress resistance in general, or methods of increasing stress resistance in a plant by introducing into a plant and expressing other isolated nucleic acid sequences encoding other

Art Unit: 1638

amino acid sequences. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

The claims are drawn to a method of increasing stress resistance to a plant which comprises increasing galactinol content in the plant body, a method of increasing stress resistance to a plant which comprises increasing galactinol content in the plant body by introducing into a plant a galactinol synthetase gene, a method of increasing stress resistance to a plant which comprises increasing galactinol content in the plant body by introducing into a plant a galactinol synthetase gene encoding a protein of SEQ ID NO:2, or a protein having galactinol synthetic activity and comprising an amino acid sequence that differs from SEQ ID NO:2 by deletion, substitution or addition of at least one or more amino acids, and a method of increasing stress resistance to a plant which comprises excessively expressing in a plant a protein of SEQ ID NO:2, or a protein having galactinol synthetic activity and comprising an amino acid sequence that differs from SEQ ID NO:2 by deletion, substitution or addition of at least one or more amino acids.

The specification discloses method of increasing drought stress resistance to a plant by introducing into and expressing in an *Arabidopsis* plant an isolated nucleic acid obtained from *Arabidopsis* encoding a galactinol synthetase designated AtGolS2 (pages 26-29 and Figures 4-8). The specification does not disclose the relationship, if any, between the isolated nucleic acid obtained from *Arabidopsis* encoding a galactinol synthetase designated AtGolS2 and the elected amino acid sequence of SEQ ID NO:2. The specification does not disclose whether this method results in increased resistance to stresses other than drought stress. The specification also does

Art Unit: 1638

not teach amino acid deletions, substitutions or additions that can be made to SEQ ID NO:2 such that the altered polypeptide retains galactinol synthetic activity, and such that the altered polypeptide confers stress resistance to a plant when excessively expressed. Additionally, the specification does not teach the expression of other isolated nucleic acids that encode galactinol synthetase and increase stress resistance. Furthermore, the specification does not teach other methods of increasing galactinol in a plant, or other methods of excessively expressing galactinol synthetase in a plant, such that stress resistance is increased.

While one of skill in the art could readily make transgenic plants expressing an isolated nucleic acid encoding a polypeptide of SEQ ID NO:2, it would require undue experimentation for one skilled in the art to determine how to express this isolated nucleic acid in a manner that would increase stress resistance, because the specification does not teach how to express an isolated nucleic acid encoding a polypeptide of SEQ ID NO:2 such that resistance to any type of stress is increased. Likewise, while one of skill in the art could readily make transgenic plants expressing an isolated nucleic acid encoding a galactinol synthetase designated AtGolS2, it would require undue experimentation for one skilled in the art to determine how to express this isolated nucleic acid in a manner that would increase resistance to stresses other than drought, because the specification does not teach the level of galactinol synthetase or galactinol required to confer resistance to stresses other than drought. Also, while one of skill in the art could readily make amino acid deletions, substitutions or additions to SEQ ID NO:2, it would require undue experimentation for one skilled in the art to determine which amino acid deletions, substitutions or additions to make in SEQ ID NO:2 such that the altered polypeptide retains galactinol synthetic activity and confers stress resistance to a plant when excessively expressed, because the

Art Unit: 1638

specification does not teach which amino acid deletions, substitutions or additions to make. To claim all modifications without any guidance as to how inoperable embodiments can be readily identified and eliminated other than by trial and error is an initiation to experiment requiring undue experimentation. Additionally, while one of skill in the art could readily make transgenic plants expressing galactinol synthetases other than an isolated nucleic acid encoding a galactinol synthetase designated AtGolS2, it would require undue experimentation for one skilled in the art to determine which galactinol synthetase to express and at what level, because the specification does not teach which other galactinol synthetases to express and at what level to confer resistance to stress. Furthermore, while one of skill in the art could readily increase galactinol or excessively express galactinol synthetase by other methods, it would require undue experimentation for one skilled in the art to determine how much to increase galactinol, and how much to excessively express galactinol synthetase to confer resistance to stress, because the specification does not teach other methods of increasing galactinol in a plant, or other methods of excessively expressing galactinol synthetase in a plant, such that stress resistance is increased.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 3-7 and 9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1, 3-7 and 9 are indefinite in the recitation of "increasing" or "increased".

"Increasing" or "increased" are relative terms that lack a comparative basis.

Art Unit: 1638

Claim 1 and 3 are indefinite in the recitation of "galactinol synthetase gene". The word gene implies DNA existing in nature that includes coding regions and noncoding regions, such as enhancers, promoters, and introns. It is suggested that the claims be amended to recite "isolated nucleic acid encoding a galactinol synthetase".

Claim 3 is indefinite in the recitation of "(c)" and "(d)", because claim 3 recites no subparts (a) and (b). It is suggested that the claim be amended to recite (a) and (b) in place of (c) and (d). In 3(d), a gene does not have galactinol synthetic activity.

Claims 3, 5, 7 and 9 are indefinite in the recitation of "galactinol synthetic activity", as "synthetic" may imply a particular method of making. It is suggested that the claims be amended to recite "galactinol synthesis activity" for clarification.

Claim 6 is rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. Claim 6 does not result in an increase in stress resistance to a plant as set forth in the preamble. Further, the gene must be expressed.

Claims 5 and 7 are indefinite in the recitation of "improving" or "improved". "Improving" or "improved" are relative terms that lack a comparative basis. It is also unclear in what way galactinol synthetic activity is improved.

Claim 9 is indefinite in the recitation of "excessively expressing". "Excessively expressing" is a relative term that lacks a comparative basis.

Claim 9 is indefinite in the recitation of "(g)" and "(h)", because claim 9 recites no subparts (a)-(f). It is suggested that the claim be amended to recite (a) and (b) in place of (g) and (h).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 6 is rejected under 35 U.S.C. 102(b) as being anticipated by Bachmann et al. (1994, Plant Physiology, Vol. 105, pages 1335-1345).

Claim 6 is drawn to a method of increasing stress resistance to a plant which comprises increasing galactinol content in the plant body.

Bachmann et al. teach a method of increasing stress resistance to a plant which comprises increasing galactinol content in the body of *Ajuga reptans* plants by cold acclimation (Table II page 1340).

Remarks

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cynthia Collins whose telephone number is (703) 605-1210.

The examiner can normally be reached on Monday-Friday 8:45 AM -5:15 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (703) 306-3218. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Application/Control Number: 09/810,506


Page 10

Art Unit: 1638

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

CC

October 16, 2002


PHUONG T. BUI
PRIMARY EXAMINER
10/16/02